Our findings show that cDC1 reprogramming progresses in situ and leads to robust, long-lasting, and systemic antitumor immunity independently of exogenous stimulation, providing a tractable strategy to induce antigen presentation and cDC1 functions in vivo and set in motion tumor antigen-specific immune responses. Here, MPPE1 is linked to neoplasm.